Bridgefront Capital LLC Invests $281,000 in Qiagen (NYSE:QGEN)

Bridgefront Capital LLC purchased a new position in shares of Qiagen (NYSE:QGEN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,316 shares of the company's stock, valued at approximately $281,000.

A number of other large investors also recently modified their holdings of the company. Groupama Asset Managment increased its position in Qiagen by 8,074.0% during the 4th quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock worth $1,416,844,000 after purchasing an additional 32,216,761 shares in the last quarter. Norges Bank acquired a new stake in shares of Qiagen in the fourth quarter worth $181,529,000. Massachusetts Financial Services Co. MA raised its stake in shares of Qiagen by 9.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock valued at $1,127,470,000 after acquiring an additional 2,202,040 shares during the period. Caisse Des Depots ET Consignations acquired a new position in shares of Qiagen during the 4th quarter valued at $53,991,000. Finally, Barclays PLC boosted its position in Qiagen by 170.6% during the 3rd quarter. Barclays PLC now owns 1,849,004 shares of the company's stock worth $84,259,000 after purchasing an additional 1,165,594 shares during the period. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Stock Down 0.7 %

QGEN traded down $0.29 during trading on Friday, hitting $41.87. The company had a trading volume of 1,823,210 shares, compared to its average volume of 1,134,961. Qiagen has a 1-year low of $37.63 and a 1-year high of $49.30. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09. The company has a market cap of $9.31 billion, a PE ratio of 116.59, a P/E/G ratio of 2.39 and a beta of 0.67. The business has a 50-day moving average of $40.67 and a 200-day moving average of $41.75.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.05. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. The business had revenue of $483.46 million during the quarter, compared to the consensus estimate of $465.66 million. During the same period last year, the firm earned $0.44 earnings per share. The company's revenue for the quarter was up 5.2% compared to the same quarter last year. As a group, analysts forecast that Qiagen will post 2.26 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on QGEN. Robert W. Baird raised their price objective on Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Redburn Atlantic downgraded Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Baird R W cut Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. UBS Group dropped their price objective on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Finally, StockNews.com upgraded shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Friday. Seven analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $48.42.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.